Redeye provides an initial comment on Safeture’s Q3 2025 report, where the company delivered a seque...
Redeye provides an initial comment on the Q3 2025 report from Sdiptech, where adjusted EBITA came in...
Redeye provides its initial take on Lagercrantz’s Q2 2025/2026 report, which featured an EBITA that ...
Redeye comments on Sleep Cycle’s Q3 report, which was in line with expectations.
Redeye updates its view on Nanologica following what we view as an undramatic Q3 2025 report.
Net sales and adj. EBIT were slightly below market consensus (LSEG) in Q3.
Redeye comments on Hexatronic’s Q3 report, beating our expectations thanks to strong development in ...
Redeye returns with a more in-depth take on the Q3 report.
Redeye reviews Alligator Bioscience’s Q3 report 2025.
Atria's Q3 2025 was strong with a 3% top line and 7% adjusted EBIT beat against LSEG Data & Analytic...
Redeye updates on Evolution after Q3 results that came in below expectations, owing to renewed weakn...
Redeye provides its initial take on MedCap’s Q3 2025 report, which came in broadly above our estimat...
* Small negative sales estimate revisions * Long term outlook is encouraging * Reiterate fair value ...
Hyresintäkterna steg med 45% till 15,5 meur och förvaltningsresultat ökade med 48% till 8,2 meur i d...
Redeye’s outlook on Dynavox remains stable after another strong report.
Redeye comments on Invisio’s Q3-results which were in line with preliminary results announced on Oct...
* Rec. PTP -4% vs ABGSCe * Occupancy flat q-o-q, as are values * Share to underperform the sector to...
Redeye keeps its Base Case and retains a positive view of Vertiseit following the Q3 report.
Vaisala’s Q3’25 results were clearly better than estimated in terms of both revenue and profitabilit...
SRV's net sales in Q3 amounted to EUR 159.7m, quite in line with our estimate of EUR 163.